Presence of allele frequency heterogeneity defined by ctDNA profiling predicts unfavorable overall survival of NSCLC

Abstract

Our results demonstrate that the presence of AFH predict unfavorable prognosis in advanced NSCLC despite which drug the patients used. The presence of AFH defined by ctDNA might provide an easily-accessible biomarker for risk stratification in the current clinical practice.